The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors

Yinghua Ji

Status: Not yet enrolling

Conditions: Malignant Tumors

Study type: Observational

Funder types: Other

Identifiers

NCT07132606

Chase 016 (Other Identifier)

CHASE 016

Details and patient eligibility

About

In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis.

This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.

Full description

Primary Objective To evaluate differential expression of serum histone succinylation between malignant solid tumor patients and healthy controls, thereby validating its early detection value.

Secondary Objectives

To determine correlations between serum histone succinylation levels and:

Tumor types Tumor stages

To statistically analyze associations of serum histone succinylation with:

Therapeutic efficacy (surgical intervention, radiotherapy, systemic therapy) Clinicopathological variables

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Case Group:

• Aged ≥18 years, regardless of sex；
• Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy；

Control Group:

• Aged ≥18 years, regardless of sex；
• Non-cancer participants enrolled through health screenings；

Exclusion criteria

• Pregnant individuals；
• Individuals with serious mental disorders or communication barriers；
• Other conditions deemed by investigators to contraindicate study participation；

Trial design

1,000 participants in 1 patient group

500 patients with malignant solid tumors

Description:

Aged ≥18 years, regardless of sex； Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy